Table 4.
The baseline characteristics of aNSCLCs who received immunotherapy.
| Characteristics | N = 92 | (%) |
|---|---|---|
| Age (years) (median, range) | 69 (45-80) | |
| Sex | ||
| Male | 64 | 69.6 |
| Female | 28 | 30.4 |
| Family history | ||
| Yes | 26 | 28.3 |
| No | 66 | 71.7 |
| Smoking history | ||
| Yes | 61 | 66.3 |
| No | 31 | 33.7 |
| Drinking history | ||
| Yes | 35 | 38 |
| No | 57 | 62 |
| ECOG performance status | ||
| 0 or 1 | 67 | 72.8 |
| ≥ 2 | 25 | 27.2 |
| The size of primary tumor (cm) | ||
| < 2 | 3 | 3.3 |
| ≥ 2 | 89 | 96.7 |
| Histological types | ||
| Adenocarcinoma | 59 | 64.1 |
| Squamous | 33 | 35.9 |
| Degree of differentiation | ||
| Low | 86 | 93.5 |
| Moderate or High | 6 | 6.5 |
| TNM stage | ||
| Ⅲ | 19 | 20.7 |
| Ⅳ | 73 | 79.3 |
| Lymph node metastasis | ||
| Yes | 65 | 70.7 |
| No | 27 | 29.3 |
| Lung metastasis | ||
| Yes | 39 | 42.4 |
| No | 53 | 57.6 |
| Braine metastasis | ||
| Yes | 13 | 14.1 |
| No | 79 | 85.9 |
| Liver metastasis | ||
| Yes | 9 | 9.8 |
| No | 83 | 90.2 |
| Bone metastasis | ||
| Yes | 26 | 28.3 |
| No | 66 | 71.7 |
| Number of metastasis sites | ||
| 0 | 12 | 13 |
| 1 | 20 | 21.8 |
| 2 | 48 | 52.2 |
| ≥ 3 | 12 | 13 |
| Response evaluation | ||
| Complete response (CR) | 0 | 0 |
| Partial response (PR) | 19 | 20.6 |
| Stable disease (SD) | 34 | 37 |
| Progressive disease (PD) | 39 | 42.4 |